Captor Therapeutics Spolka Akcyjna (WSE:CTX)

Market Cap	479.68M +141.8%
Revenue (ttm)	2.38M -82.9%
Net Income	-42.65M
EPS	-7.71
Shares Out	6.35M
PE Ratio	n/a
Forward PE	100.99
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,638
Open	75.20
Previous Close	75.50
Day's Range	73.30 - 75.80
52-Week Range	31.30 - 89.20
Beta	0.56
Analysts	Strong Buy
Price Target	86.83 (+14.55%)
Earnings Date	Sep 15, 2026

About WSE:CTX

Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, focuses on the discovery and development of protein degradation drugs for cancer and autoimmune diseases. The company provides Targeted Protein Degradation technology that overcomes many existing drug limitations by removing proteins resistant to available therapeutics. Its products in various stages of development include CT-03, which has completed the Phase 1 clinical trials for the treatment of non-small cell lung cancer, triple-negative breast cancer, as well as cancers of the...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 82
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: CTX

Financial Performance

In 2025, WSE:CTX's revenue was 4.66 million, a decrease of -70.55% compared to the previous year's 15.83 million. Losses were -42.00 million, 9.29% more than in 2024.